ViiV Healthcare has announced that its once-a-month shot, designed as an alternative to daily doses of HIV treatment drugs, has met primary endpoints in a pair of pivotal phase III studies.
Comprehensive data from ATLAS and FLAIR studies presented at the 2019 Conference on Retroviruses and Opportunistic Infections show the investigational long-acting injectable to be effective in maintaining viral suppression. The injection combines Johnson & Johnson’s rilpivirine with cabotegravir, which is being developed by ViiV, a joint venture of GlaxoSmithKline, Pfizer and Japan’s Shionogi.
ViiV plans to apply for regulatory approval later this year, hoping to launch the product at the start of 2020.
Read the press release.
